Quick Answer
BICYCLE THERAPEUTICS PLC reported Research And Development Expense of $240.28 million for the year ending 2025.
- BICYCLE THERAPEUTICS PLC showed an increase of +38.9% in Research And Development Expense from 2024 to 2025.
- This data is from BICYCLE THERAPEUTICS PLC's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $4.92 million | Q3 2018: $5.64 million | Q1 2019: $6.28 million | Q2 2019: $6.54 million | Q3 2019: $6.08 million | Q1 2020: $7.77 million | Q2 2020: $7.96 million | Q3 2020: $7.36 million | Q1 2021: $9.69 million | Q2 2021: $11.72 million | Q3 2021: $10.51 million | Q1 2022: $14.28 million | Q2 2022: $19.85 million | Q3 2022: $22.75 million | Q1 2023: $32.21 million | Q2 2023: $39.72 million | Q3 2023: $39.87 million | Q1 2024: $34.86 million | Q2 2024: $40.06 million | Q3 2024: $48.27 million | Q1 2025: $59.06 million | Q2 2025: $71.03 million | Q3 2025: $58.43 million.
- Over the full 9 years of available data (2017 to 2025), BICYCLE THERAPEUTICS PLC's Research And Development Expense has grown by 1,925.0%.
- Historical annual values: Fiscal year 2025: $240.28 million | Fiscal year 2024: $172.97 million | Fiscal year 2023: $156.50 million | Fiscal year 2022: $81.61 million | Fiscal year 2021: $44.88 million | Fiscal year 2020: $33.15 million | Fiscal year 2019: $25.54 million | Fiscal year 2018: $20.76 million | Fiscal year 2017: $11.87 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: